Alx Oncology Holdings (ALXO) Assets Average (2020 - 2026)
Alx Oncology Holdings (ALXO) posted Assets Average of $118.7 million for Q1 2026, up 67.44% sequentially from $70.9 million in Q4 2025, and down 11.65% YoY from $134.3 million in Q1 2025.
Alx Oncology Holdings (ALXO) Assets Average (2020 - 2026) Analysis & Trends
Alx Oncology Holdings has reported Assets Average for 7 years, with the latest figure at $118.7 million in Q1 2026.
- Quarterly Assets Average fell 11.65% year-over-year to $118.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $118.7 million (down 11.65% YoY) and the FY2025 annual result came in at $103.4 million, down 47.01% from the prior year.
- Assets Average rose to $118.7 million in Q1 2026 per ALXO's latest filing, from $70.9 million in the prior quarter.
- Over five years, Assets Average peaked at $371.9 million in Q1 2022 and troughed at $70.9 million in Q4 2025.
- A 5-year average of $218.7 million and a median of $227.6 million in 2024 frame the typical range for Assets Average.
- The sharpest annual moves came in 2025 and 2026: Assets Average tumbled 57.49% in 2025, then retreated 11.65% in 2026.
- Over 5 years, Assets Average stood at $312.1 million in 2022, then fell by 25.88% to $231.3 million in 2023, then decreased by 27.92% to $166.7 million in 2024, then sank by 57.49% to $70.9 million in 2025, then jumped by 67.44% to $118.7 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $118.7 million, $70.9 million, and $89.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Alx Oncology Holdings | 270.90 Mn | 270.90 Mn | - | 169.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 169.57 Mn |
| Mar 31, 2026 | 118.69 Mn |
| Dec 31, 2025 | 70.88 Mn |
| Sep 30, 2025 | 89.02 Mn |
| Jun 30, 2025 | 108.11 Mn |
| Mar 31, 2025 | 134.34 Mn |
| Dec 31, 2024 | 166.75 Mn |
| Sep 30, 2024 | 200.17 Mn |
| Jun 30, 2024 | 213.63 Mn |
| Mar 31, 2024 | 227.60 Mn |
| Dec 31, 2023 | 231.33 Mn |
| Sep 30, 2023 | 233.02 Mn |
| Jun 30, 2023 | 262.04 Mn |
| Mar 31, 2023 | 292.31 Mn |
| Dec 31, 2022 | 312.09 Mn |
| Sep 30, 2022 | 331.85 Mn |
| Jun 30, 2022 | 354.85 Mn |
| Mar 31, 2022 | 371.93 Mn |
| Dec 31, 2021 | 389.96 Mn |
| Sep 30, 2021 | 410.51 Mn |